(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/235780 A1

(51) International Patent Classification:
A61K 48/00 (2006.01) *A61K 38/18* (2006.01)
A61P 27/02 (2006.01)

(21) International Application Number:
PCT/US2022/027647

(22) International Filing Date:
04 May 2022 (04.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/185,889 07 May 2021 (07.05.2021) US

(71) Applicant: **OYSTER POINT PHARMA, INC.** [US/US]; 202 Carnegie Center, Suite 109, Princeton, New Jersey 08540 (US).

(72) Inventors: **NAU, Jeffrey Alan**; c/o Oyster Point Pharma, Inc., 202 Carnegie Center, Suite 109, Princeton, New Jersey 08540 (US). **CARLSON, Eric C.**; c/o Oyster Point Pharma, Inc., 202 Carnegie Center, Suite 109, Princeton, New Jersey 08540 (US).

(74) Agent: **MAYER, Mika R.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, DC 20004-2400 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF




FIG. 13A




FIG. 13B




FIG. 13C

(57) Abstract: Provided are recombinant adeno-associated virus (rAAV) virions, methods of treating an ocular condition, pharmaceutical compositions, and other compositions and methods, in which the rAAV virion comprises a polynucleotide encoding a neurotrophic factor, such as Nerve Growth Factor (NGF) or Glial Derived Neurotrophic Factor (GDNF). Methods of treatment may include administration to the lacrimal gland.

WO 2022/235780 A1